]>
IRCT201112178428N1 IRCT 2014-04-19 Research Deputy of Hamadan University of Medical Sciences A comparison of the efficacy of Plavix and Osivix in patients undergoing Coronary artery by pass A comparison of the effectiveness, side effects and acceptability of Plavix and Osivix as anti platelet tablets in patients undergoing Coronary artery by pass. 2012-02-05 anticipated 80 Complete https://irct.ir/trial/8887 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Heart disease. Intervention 1: at this clinical trial study, the control group consists of 40 patients recieve Plavix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each group. It should be noted that all patients receive 100 mg aspirin tablet daily. In order to implementation of Ex-vivo analysis, blood is mixed with 3.8% citrate and platelet aggregometry is conducted. The amount of Adenosine diphosphate, platelet-rich plasma and platelet count is measured as indicating factors of aggrigation. Intervention 2: at this clinical trial study, the intervantion group consists of 40 patients recieve Osvix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each group. It should be noted that all patients receive 100 mg aspirin tablet daily. In order to implementation of Ex-vivo analysis, blood is mixed with 3.8% citrate and platelet aggregometry is conducted. The amount of Adenosine diphosphate, platelet-rich plasma and platelet count is measured as indicating factors of aggrigation.
public Behzad Imani
Operating-room departemnt, Hamadan University of Medical Sciences, Mahdieh St., Hamadan, Iran.
Hamadan Iran (Islamic Republic of) +98 81 1838 1017 b.imani@umsha.ac.ir Hamadan University of Medical Sciences scientific Reza Safiaryan
Surgery Departemnt, Hamadan University of Medical Sciences, Mahdieh St., Hamadan, Iran.
Hamadan Iran (Islamic Republic of) +98 81 1252 0684 safiaryan@umsha.ac.ir Hamadan University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: All patients undergoing open heart surgery Exclusion criteria: 1- Patients with a prior events of acute coronary syndrome, 2- Hepatic insufficiency, 3- History of significant bleeding disorder,4- Those already taking anti-platelet and/or anticoagulant therapy, 5- Age less than 20 and over than 75. 20 years 75 years Both I97.1 Other functional disturbances following cardiac surgery Treatment - Drugs Treatment - Drugs at this clinical trial study, the control group consists of 40 patients recieve Plavix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each group. It should be noted that all patients receive 100 mg aspirin tablet daily. In order to implementation of Ex-vivo analysis, blood is mixed with 3.8% citrate and platelet aggregometry is conducted. The amount of Adenosine diphosphate, platelet-rich plasma and platelet count is measured as indicating factors of aggrigation. at this clinical trial study, the intervantion group consists of 40 patients recieve Osvix tablets as an antiplatetlet agent. The prescribed dose is 75 mg of Clopidogrel per day for each group. It should be noted that all patients receive 100 mg aspirin tablet daily. In order to implementation of Ex-vivo analysis, blood is mixed with 3.8% citrate and platelet aggregometry is conducted. The amount of Adenosine diphosphate, platelet-rich plasma and platelet count is measured as indicating factors of aggrigation. Platelet-rich plasma. Timepoint: 30 days after heart surgery. Method of measurement: Aggregometry. Adenosine diphosphate. Timepoint: 30 days after heart surgery. Method of measurement: Aggrigometry. Research Deputy of Hamadan University of Medical Sciences Approved 2012-12-17 Hamadan University of Medical Sciences Reseach Deputy, Hamadan University of Medical Scinces, Hamadan, Iran. Hamadan Iran (Islamic Republic of)